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Abstract 25 
Objectives:  To explore the effect of low incubation temperatures and the consequent 26 
slowing of bacterial metabolism on the bactericidal action of anti-tuberculosis drugs 27 
against Mycobacterium tuberculosis. 28 
Methods:  Counting of surviving bacteria during exposure of static cultures to isoniazid 1 29 
mg/mL, rifampicin 2 mg/mL, TMC207 0.5 or 2 mg/mL and pyrazinamide 40 or 160 30 
mg/mL drugs, usually for periods of 21 days at temperatures of 37, 25, 22, 19. 16 or 8oC  31 
Results: The bactericidal activities of isoniazid and rifampicin were progressively 32 
reduced at 25oC and 22oC, and were minimal at lower temperatures.    TMC207 was 33 
immediately bactericidal at 37oC, in contrast to the early static phase reported with log 34 
phase cultures, and showed less change in activity as incubation temperatureswere 35 
reduced than did rifampicin or isoniazid.   Pyrazinamide was more bactericidal when 36 
incubation temperatures were reduced below 37oC and when the static seed cultures were 37 
most dormant.   38 
Conclusions: These results can be explained by the surmise that at low temperatures 39 
bacterial energy is at a low level with only just sufficient ATP to maintain homeostasis, 40 
making them more susceptible to the blocking of ATP synthesis by TMC207.  41 
Insufficient ATP at low temperature would also hinder the export of pyrazinoic acid, the 42 
toxic product of the pro-drug pyrazinamide, from the mycobacterial cell by an inefficient 43 
efflux pump which requires energy. 44 
 45 
 46 
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 47 
1. Introduction 48 
Perhaps the most important issue in understanding the chemotherapy of tuberculosis is 49 
why it takes so long to kill Mycobacterium tuberculosis in the lesions of patients when 50 
axenic cultures can be sterilized in much shorter periods.  The tolerance of these 51 
persistent bacilli to antibacterial drugs is characterized by the cessation of multiplication 52 
and a slowing of metabolism, so that inhibition of cellular biochemical machinery after 53 
drug exposure is less effective in killing the cell.1,2  A variety of in vitro model systems 54 
have been proposed to mimic in vivo M. tuberculosis populations and interrogate drug 55 
action, 3-5 but none have identical transcriptional signatures to those found by global gene 56 
expression profiling of the “fat and lazy” bacilli encountered in the sputum of patients 57 
with pulmonary tuberculosis6 or from bacilli isolated from human lung sections.7  58 
Furthermore, most model systems use culture media at the conventional pH of 6.6-6.8 59 
whereas lesions must be more acid in the range of pH 5.5-6.0 to account for the known 60 
bactericidal activity of pyrazinamide whilst allowing multiplication of M. tuberculosis.8,9  61 
In the search for inexpensive model systems that would be more representative of 62 
persistent bacilli and yet easy to use in assays extending for several weeks, we decided to 63 
explore the effects of lowering the incubation temperature from 37 oC to 25oC  where 64 
multiplication ceases but metabolism continues, to lower temperatures that likely reduce 65 
metabolism further. We used a static stationary phase culture, with characteristic 66 
adaptations of persistence including anaerobic respiration and energy production from β-67 
oxidation of fatty acids,10,11 at pH 6.0 to allow the action of pyrazinamide to be explored.  68 
The other drugs tested were the first line drugs isoniazid and rifampicin together with the 69 
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diarylquinoline TMC207 (previously R207910) which inhibits mycobacterial ATP 70 
synthase, because it is the first of the new drugs being developed and has been shown to 71 
be promising both in its characteristics12 and in the preliminary results of clinical trials.13  72 
 73 
Methods 74 
Bacterial Strain.  M. tuberculosis, strain H37Rv. 75 
Chemicals. TMC207 was gift from Tibotec Pharmaceuticals (Beerse, Belgium). Other 76 
antibacterial compounds were purchased from Sigma. All other chemicals were obtained 77 
from VWR International (Magna Park, Leics, UK) except where specified otherwise.  78 
Media.  Dubos broth buffered to pH 5.95 was prepared as follows:  To 850 mL distilled 79 
water, 8.2g KH2PO4 and 3.2g K2HPO4 was added and mixed until dissolved. Then 50 mL 80 
glycerol and 6.5g Dubos broth base (Difco 238510, Becton-Dickinson, Sparks, MD) was 81 
added and mixed on a magnetic stirrer until dissolved. The pH was adjusted to 5.90 with 82 
1M citric acid (approximately 5mL), to give a final pH of 5.95+/-0.05.  The medium was 83 
sterilized through a 0.2 µm filter.   Dubos Medium Albumin (Difco 230910, Becton-84 
Dickinson, Sparks, MD) 100 mL was added to complete the medium.  85 
Serial 10-fold dilutions of Dubos broth cultures in 100 µL volumes  were plated onto 86 
Mycobacteria 7H11 agar (Difco 283810, Becton-Dickinson, Sparks, MD) supplemented 87 
with 100 mg/L oleic acid, albumin, dextrose enrichment (BBL212260, Becton-Dickinson, 88 
Sparks, MD) and  50 mg/L of the broad spectrum antifungal carbendazim (Aldrich). 89 
Plates were incubated in the dark at 37oC for 28 days, when colonies were counted. 90 
Anti-bacterial compounds. TMC207 5 mg/mL stock solution in sterile dimethyl 91 
sulphoxide was added at final concentrations of 0.5 and 2.0 mg/L.  Pyrazinamide 10 mg/ 92 
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stock solution in sterile, distilled water; final concentrations of 30, 40 and 160 mg/L. 93 
Rifampicin 10 mg/mL stock solution in sterile, absolute methanol; final concentration 2 94 
mg/L.  Isoniazid 10 mg/mL stock solution in sterile, distilled water; final concentration 1 95 
mg/L. The drug concentrations used correspond with concentrations near peak and near 96 
trough obtained in patients under treatment14 except that 160 mg/L pyrazinamide is well 97 
above peak concentration to see what effect higher concentrations would have.  98 
Culture systems.  The seed inoculum was prepared by growing M. tuberculosis in Dubos 99 
broth to an opacity of 0.4-0.6 at 580 nm and storing aliquots frozen in liquid nitrogen.  100 
Aliquots were pre-tested for the presence of contaminants.  In each experiment, a series 101 
of 10 mL volumes of buffered Dubos broth at pH 5.95 were dispensed into 28 mL glass 102 
screw-capped tubes, which were inoculated with 100 µL seed culture and either, in 103 
procedure 1, incubated undisturbed for 30 days or, in procedure 2, incubated until they 104 
reached standard opacity (McFarland 2) and then inoculated at a 1:4 by volume dilution 105 
into fresh buffered Dubos broth at pH 5.95 and incubated undisturbed for 30 days.  The 106 
cultures from either procedure were then vortex-mixed to create an even suspension, 107 
antibacterial compounds were added, and serial samples taken for colony counting at 3, 7, 108 
14 and 21 days post exposure after incubation at various temperatures.  At least two 109 
replicates of each antibacterial compound concentration were tested. 110 
Incubation temperatures. The 28 mL screw-capped tubes were incubated either in a 111 
small conventional incubator with an adjustable temperature or in a Boekel PCB2 cooling 112 
incubator (Grant Instruments, Cambridge) at temperatures of 8, 16, 19, 22, 25 and 37 oC. 113 
Statistics.  Counts and linear regression coefficients were calculated in Excel and were 114 
further examined by ANOVA in Stata 8 (Stata Corp., College Station, TX) 115 
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 117 
Results 118 
Drug-free cultures. Control cultures  (no drug) grown at 37oC increased their cfu count 119 
by about 1 log unit over 21 days, whereas cultures grown at lower temperatures including 120 
25oC showed no change in their counts over this incubation period. 121 
Inoculum of 10-day static cultures.  We first exposed static 10-day cultures to 2 mg/L 122 
rifampicin, 1 mg/L TMC207 or 30 or 160 mg/L pyrazinamide at 37, 25, 19 and 8oC.  123 
Linear regression coefficients were calculated from cfu counts over 7 days of incubation 124 
(Fig 1).  None of the drugs had bactericidal activity at 8oC.  The bactericidal activity of 125 
rifampicin was the greatest at 37oC, but declined sharply at 25oC and 19oC.   TMC207 126 
was less bactericidal than rifampicin at 37oC but its activity dropped more slowly at 25 127 
and 19oC.   The difference in behaviour between rifampicin and TMC207 was highly 128 
significant (p<0.001).  Pyrazinamide at both concentrations allowed slight growth at 37oC 129 
but were marginally bactericidal at 25oC and 19oC. 130 
Inoculum of 30-day static cultures using procedure 1.  To extend these findings of a 131 
drug-specific effect of incubation temperature, we exposed static 30-day cultures for 21 132 
days to 2 mg/L rifampicin, 1 mg/L isoniazid, 0.5 and 2 mg/L TMC207 or 40 or 160 mg/L 133 
pyrazinamide at 37, 25, and 19oC.  Cultures were also exposed to the same drugs at 22oC 134 
and at 16oC in additional follow up experiments.  The counts on RIFAMPICIN (Fig 2) 135 
show an almost exponential decline, most rapid at 37oC, less at 25oC and at similar 136 
slower rates of killing at 22, 19 and 16oC.  The counts on isoniazid (Fig 3) at 37oC 137 
showed a rapid decline of 3 log units during the first 7 days of exposure followed by no 138 
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loss of viability to 21 days.  At 25oC, the initial fall was about 2 log units, while at lower 139 
temperature only a very slight decline occurred throughout   The counts on 2 mg/L 140 
TMC207 showed an exponential fall at 37oC (Fig 4), starting with an initial substantial 141 
fall during the first 3 days, and with a slight reduction, much less than with either 142 
rifampicin or isoniazid, in the rate of fall at the lower temperatures. The counts on 160 143 
mg/L pyrazinamide showed little change over the 21 days at 37oC, but increased 144 
bactericidal activity with similar steady falls at 19 and 25oC (Fig 5).  Linear regressions 145 
of the viable counts,  which estimate overall bactericidal activity, were calculated for 146 
isoniazid over 0-7 days during which period all bactericidal activity occurred and for the 147 
remaining drugs over 0-21 days since their bactericidal activity was more prolonged (Fig 148 
6).  The loss of bactericidal activity as temperature was lowered was most evident with 149 
rifampicin and isoniazid.  The corresponding fall in activity for TMC207 at both 150 
concentrations was smaller than with rifampicin or isoniazid.   In contrast to the other 151 
drugs, the bactericidal activity of pyrazinamide at both concentrations increased with 152 
temperatures below 37oC. 153 
Inoculum of 30-day static cultures using procedure 2. To confirm the enhanced 154 
efficacy of pyrazinamide at low temperature in a model where isoniazid-mediated killing 155 
was not so prominent, we adopted a second culture system (procedure 2) and re-tested 156 
pyrazinamide and isoniazid killing. In procedure 1 for preparation of the test inoculum, 157 
isoniazid at 37oC caused a drop of approximately 3 log units during the first 7 days (Fig 158 
3A), whereas  in procedure 2 cultures only a 1 log unit reduction in cfu was detected after 159 
isoniazid exposure (Fig 3B).  Drug-free control cultures grew successfully at 37 oC, and 160 
there was no change in viable count over time at 25 or 22 oC, as expected. The viable 161 
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counts during exposure to 40 and 160 mg/L pyrazinamide demonstrate unequivocally that 162 
reductions in incubation temperature from 37oC to 25oC resulted in a striking increase in 163 
bactericidal activity which was even greater at 22oC (Fig 7).  At 37oC, pyrazinamide at 164 
either concentration had negligible bactericidal activity, but at 22oC the counts on 165 
cultures exposed to 40 µmg/L pyrazinamide dropped from log 7.7 cfu/mL to log 5.4 166 
cfu/mL (2 log kill) over 21 days, while those exposed to 160 µmg/L pyrazinamide 167 
dropped even further to log 4.3 cfu/mL (3 log kill). 168 
 169 
 170 
Discussion 171 
The most striking finding of this study was the increase in bactericidal activity of 172 
pyrazinamide at temperatures below 37oC, particularly evident when the test cultures had 173 
been prepared by procedure 2 (Fig7).  This preparation procedure was hypothesized to 174 
increase the resemblance of the test cultures to persistent M. tuberculosis in sputum and 175 
presumably also in lesions because isoniazid exposure caused an initial drop of about 1 176 
log unit in counts Fig 3B). This is similar to the drop in viability demonstrated during the 177 
first week of early bactericidal studies on patients given isoniazid monotherapy, 15 and is 178 
consistent with evidence suggesting that isoniazid-tolerance may be a feature of persistent 179 
bacilli.5,16  This drop of 1 log unit using procedure 2 is appreciably smaller than the 180 
reduction of 3 log units using bacilli prepared by procedure 1 (Fig 3A), and is, as 181 
predicted, inversely correlated with pyrazinamide efficacy in these models.  An 182 
explanation for the increase in bactericidal activity of pyrazinamide at low temperatures 183 
is provided by the Zhang hypothesis for the mode of action of pyrazinamide.8   According 184 
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to this hypothesis, pyrazinmide is deaminated in the cytoplasm of bacilli and the resulting 185 
pyrazinoic acid is pumped out to the micro-environment.  It is then passively reabsorbed 186 
in a pH-dependent manner into the bacilli.  Once inside, bacilli are required to actively 187 
pump pyrazinoic acid out again.  If the mycobacterial energy supply is diminished, 188 
pyrazinoic acid accumulates within the cell, eventually killing it.17  Thus, the elimination 189 
of pyrazinoic acid is energy-dependent. If ATP levels are diminished by sustained 190 
incubation at low temperature, pyrazinoic acid will accumulate more rapidly, and killing 191 
will occur more readily.  The finding that the bactericidal activity was greater in 192 
procedure 2 than in procedure 1 test cultures indicates that less energy, perhaps in the 193 
form of ATP, was available in the non-replicating procedure 2 cultures. This hypothesis 194 
is consistent with ATP measurements, and transcriptional signatures of energy production 195 
and ribosomal biosynthesis, showing a reduction in ATP levels in hypoxic non-196 
replicating in vitro models of persistence.6,10, 18-20 The bactericidal activity of 197 
pyrazinamide is therefore at a maximum when the energy sources available to the bacilli 198 
are at their lowest, either because metabolism is limited by adaptation to the in vivo 199 
environments encountered or by low incubation temperatures. 200 
  The second finding of interest was the rapid onset of the bactericidal activity of 201 
TMC207 at 37oC evident during the first 3 days of exposure.  This rapid onset is in 202 
contrast to the existence of an initial phase lasting 7-14 days when no change in the cfu 203 
count occurs after exposure of log phase bacilli to TMC207.12,21  The results from log 204 
phase organisms gave rise to the view that TMC207 has time dependent but not dose 205 
dependent activity.12  We suggest that the gradual use of the energy store available in log 206 
phase bacilli is responsible for the static phase, which is eventually followed by rapid 207 
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dose-dependent killing when ATP levels are low and the effects of the ATP synthase 208 
isoniazidibitor become cidal.   A further feature of interest was the small decrease in the 209 
bactericidal activity of TMC207 as the incubation temperature was reduced compared to 210 
the larger effects on the bactericidal activities of rifampicin and isoniazid (Fig 6).  Since 211 
bacterial metabolism is likely to progressively decrease as the temperature goes down, 212 
TMC seems to retain its activity even when metabolism is low. This indicates its potential 213 
value as a drug capable of sterilizing the more persistent bacterial populations, and 214 
identifies energy generation as important for maintenance of cell viability in bacilli 215 
isolated from in vitro models of persistence.18-20  This effect may be noticeable because 216 
TMC207 was considerably less bactericidal at 37oC than rifampicin or isoniazid, but this 217 
greater kill caused by isoniazid and rifampicin may not be reflected by a similar greater 218 
activity in treating patients because their half-life and therefore the period of exposure to 219 
the drugs in lesions is considerably shorter than that of TMC207.12,14   220 
In brief, the effects of reducing the incubation temperature are particularly illuminating in 221 
exploring the action of drugs, such as pyrazinamide and TMC207 whose activity is 222 
greatly dependent on the energy resource status of bacilli. 223 
 224 
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 301 
Fig 1.  The speed of bactericidal activity of rifampicin (RIF) 2 mg/L, TMC207 (TMC) 1 302 
mg/L or pyrazinamide (PZA) 30 or 160 mg/L against 10-day static cultures of M. 303 
tuberculosis at incubation temperatures of 37, 25, 19 or 8oC.  Speed is represented by the 304 
linear regression coefficients for log cfu/mL/day. 305 
 306 
Fig 2. Survival curves for 30-day static cultures of M. tuberculosis exposed to rifampicin 307 
(RIF) 2 mg/L for 21 days at temperatures ranging from 37oC to 16oC. 308 
 309 
Fig 3. A. Survival curves for 30-day static procedure 1 cultures of M. tuberculosis 310 
exposed to isoniazid 1 mg/L for 21 days at temperatures ranging from 37oC to 16oC 311 
B. Survivor curves for 30-day static procedure 2 cultures exposed to isoniazid (INH) 1 312 
mg/L at 37oC. 313 
 314 
Fig 4. Survival curves for 30-day static cultures of M. tuberculosis exposed to TMC207 2 315 
mg/L for 21 days at temperatures ranging from 37oC to 16oC 316 
 317 
Fig 5. Survival curves for 30-day static cultures (procedure 1) of M. tuberculosis exposed 318 
to pyrazinamde 160 mg/L for 21 days at temperatures ranging from 37oC to 16oC 319 
 320 
Fig 6. The speed of bactericidal activity of rifampicin (RIF) 2 mg/L, TMC207 (TMC) 2 321 
mg/L or pyrazinamide (PZA) 40 or 160 mg/L against 10-day static cultures of M. 322 
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tuberculosis at incubation temperatures of 37, 25, 19 or 16oC.  Speed is represented by 323 
the linear regression coefficients for log cfu/mL/day. 324 
 325 
Fig 7. Experiments 4. Survival curves for 30-day static cultures (procedure 2) of M. 326 
tuberculosis exposed to pyrazinamde 40 or 160 mg/L for 21 days at temperatures of A. 327 
37oC or B. at  25oC or 22oC. 328 
 329 
 330 
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